Experimental cell therapy takes on advanced cancers
NCT ID NCT07482319
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have not responded to standard treatments. GK01 uses a patient's own immune cells, trained to attack their cancer. The main goal is to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GK01 cell injection (patient's own immune cells trained to attack tumors)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 15 participants, focused on safety and dosing. It may not show any benefit, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.